MARIPOSA by OncoPharmPod published on 2024-06-27T14:21:59Z The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.
